STML-ELA-0422 Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

In this study, we are testing a new endocrine therapy, called elacestrant, that is an endocrine therapy that stops hormones from attaching to cancer cells and helping them grow. Researchers would like to understand if switching SoC to elacestrant (the study drug) will help to slow down or stop the growth of cancer.